Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs by Krüger, Martina et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Poster presentation
Protein kinase G modulates human myocardial passive stiffness by 
phosphorylation of the titin springs
Martina Krüger*1, Sebastian Kötter1, Anika Grützner1, Patrick Lang1, 
Christian Andresen1, argaret M Redfield2, Elke Butt3, Cris G dos Remedios4 
and Wolfgang A Linke1
Address: 1Physiology and Biophysics Unit, University of Muenster, D-48149 Muenster, Germany, 2Mayo Foundation, Rochester, MN 55905, USA, 
3Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, D-97080 Wurzburg, Germany and 4Muscle Research Unit, 
Bosch Institute, University of Sydney, Sydney 2006, Australia
Email: Martina Krüger* - makruger@uni-muenster.de
* Corresponding author    
Background
The sarcomeric titin springs influence myocardial disten-
sibility and passive stiffness. Titin-isoform composition
and protein kinase-A (PKA) dependent titin phosphoryla-
tion are variables contributing to diastolic heart function.
However, diastolic tone, relaxation speed, and left-ven-
tricular extensibility are also altered by protein kinase-G
(PKG) activation. We used back-phosphorylation assays
to determine whether PKG can phosphorylate titin and
affect titin-based stiffness in skinned myofibers and iso-
lated myofibrils.
Results
PKG in the presence of 8-pCPT-cGMP (cGMP) phosphor-
ylated the two main cardiac-titin isoforms, N2BA and
N2B, in human and canine left ventricle. In human
myofibers/myofibrils dephosphorylated prior to mechan-
ical analysis, passive stiffness dropped 10–20% upon
application of cGMP-PKG. Autoradiography and anti-
phosphoserine blotting of recombinant human I-band-
titin domains established that PKG phosphorylates titin's
N2-B and N2-A domains. Using site-directed mutagenesis,
serine residue S469 near the COOH-terminus of the car-
diac N2-B-unique sequence (N2-Bus) was identified as a
PKG and PKA phosphorylation site. To address the mech-
anism of the PKG-effect on titin stiffness, single-molecule
AFM force-extension experiments were performed on
engineered N2-Bus-containing constructs. The presence of
cGMP-PKG increased the bending rigidity of the N2-Bus
to a degree that explained the overall PKG-mediated
decrease in cardiomyofibrillar stiffness. Thus, the
mechanically relevant site of PKG-induced titin phospho-
rylation is most likely in the N2-Bus; phosphorylation of
other titin sites could affect protein-protein interactions.
Conclusion
The results suggest that reducing titin stiffness by PKG-
dependent phosphorylation of the N2-Bus can benefit
diastolic function. Failing human hearts revealed a deficit
for basal titin phosphorylation compared to donor hearts,
which may contribute to diastolic dysfunction in heart
failure.
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